Sage Therapeutics shares are trading lower after the company reported worse-than-expected Q3 EPS results. Additionally, HC Wainwright & Co. cut its price target on the stock from $25 to $14.
Portfolio Pulse from Benzinga Newsdesk
Sage Therapeutics shares declined following disappointing Q3 EPS results and a price target cut by HC Wainwright & Co. from $25 to $14.
October 30, 2024 | 3:21 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sage Therapeutics shares are down due to worse-than-expected Q3 EPS results and a price target reduction by HC Wainwright & Co. from $25 to $14.
The company's shares are negatively impacted by the disappointing Q3 EPS results, which indicate weaker financial performance than anticipated. The price target cut by HC Wainwright & Co. further pressures the stock, suggesting reduced future valuation expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100